Results 111 to 120 of about 24,077 (195)

Generalized Chorea and JAK2V617F Mutation-Positive Myeloproliferative Disorders. [PDF]

Mov Disord Clin Pract, 2020
Betté S, Moore H.
europepmc   +1 more source

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. [PDF]

Leukemia, 2020
Breccia M, Piciocchi A, De Stefano V, Finazzi G, Iurlo A, Fazi P, Soddu S, Martino B, Palandri F, Siragusa S, Albano F, Passamonti F, Vignetti M, Vannucchi AM.   +13 more
europepmc   +1 more source

Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of N-terminal pro-B-type natriuretic peptide and vascular endothelial growth factor - a pilot study. [PDF]

Arch Med Sci, 2021
Költő G, Tőkés-Füzesi M, Papp E, Adravetz Z, Komócsi A, Egyed M, Faludi R.   +6 more
europepmc   +1 more source

Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front‐line hypomethylating agents and venetoclax: A retrospective Italian study

British Journal of Haematology, Volume 209, Issue 2, Page 799-803, August 2026.
Ilaria Tanasi, Edoardo Tamellini, Elena Marchetti, Eleonora De Bellis, Cristina Ancora, Francesco Angotzi, Davide Facchinelli, Francesca Capraro, Giulia Battaglia, Alessandra Sperotto, Michele Gottardi, Matteo Leoncin, Mauro Krampera, Mario Tiribelli, Carmela Gurrieri   +14 more
wiley   +1 more source

Myeloproliferative disorders: let the partner guide!

Haematologica, 2007
Olivier Rosnet, Daniel Birnbaum
doaj   +1 more source

Analytical cohort study on splenomegaly and cytopenias in myeloproliferative disorders. [PDF]

Bioinformation
Sinha S, Rajan VP, Nair AU, Jakka AP, Chandrasekaran SP.   +4 more
europepmc   +1 more source

Pediatric Pulmonary Hypertension Associated With Treatment of Myeloproliferative Disorders and Malignant Tumors. [PDF]

Pulm Circ
Chida-Nagai A, Terashita Y, Hirabayashi S, Yamazawa H, Cho Y, Manabe A.   +5 more
europepmc   +1 more source

Clinical course and short-term outcome of postsplenectomy reactive thrombocytosis in children without myeloproliferative disorders: A single institutional experience from a developing country. [PDF]

PLoS One, 2020
Zvizdic Z, Kovacevic A, Milisic E, Jonuzi A, Vranic S.   +4 more
europepmc   +1 more source

SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2. [PDF]

EMBO Mol Med
Cho HJ, Smith J, Switzer CH, Louka E, Charles RL, Prysyazhna O, Schroder E, Fernandez-Caggiano M, de Jesus DS, Eminaga S, Yin X, Yang X, Lynham S, Mayr M, Morales V, Bianchi K, Rajeeve V, Cutillas PR, Mead AJ, Eaton P.   +19 more
europepmc   +1 more source

The Association Between Janus Kinase 2 and Factor V Leiden Mutations and Thrombotic Complications in Patients With Myeloproliferative Disorders: A Study From Saudi Arabia. [PDF]

Cureus
Sayed WS, Al-Bayati A, Elzubair LG, Mohamed S, Alharthi M.   +4 more
europepmc   +1 more source